title: [Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure].
abstract: The follow-up and treatment of thyroid cancer presents several aspects subject to discussion, such as its management in patients with End-Stage Renal Failure (ESRF). We present a patient with ESRF and papillary thyroid carcinoma, which had to be coordinated among different departments (Endocrinology, Nuclear Medicine, Nephrology and Physics and Radiation Protection). Both the diagnostic scintigraphy with (123)I and the ablative treatment with (131)I performed later were performed with the administration of rh TSH. The room in which the metabolic therapy was to be performed was prepared for the patient's periodic hemodialysis. The (131)I dose used was 80% of the usual dose. This made it possible to assure the therapeutic effect and that the patient's stay in hospital would only be for 5 days. Throughout the whole diagnostic and therapeutic process, no adverse effects attributable to rh TSH or radioiodine were observed. The coordination among the departments involved enabled an effective and safe process for the patient.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Clínico Universitario "Lozano Blesa" de Zaragoza, Zaragoza, España. aandresgr@salud.aragon.es
authors.forename: A
authors.initials: A
authors.lastname: Andres
authors.forename: L
authors.initials: L
authors.lastname: Tardín
authors.forename: A
authors.initials: A
authors.lastname: Santapau
authors.forename: P
authors.initials: P
authors.lastname: Razola
authors.forename: E
authors.initials: E
authors.lastname: Prats
authors.forename: A
authors.initials: A
authors.lastname: Parra
authors.forename: M A
authors.initials: MA
authors.lastname: Rivas
authors.forename: P
authors.initials: P
authors.lastname: Ruiz
authors.forename: R
authors.initials: R
authors.lastname: Alvarez
authors.forename: A
authors.initials: A
authors.lastname: Camara
authors.forename: J
authors.initials: J
authors.lastname: Banzo
mesh_terms: D000328:Adult; D002291:Carcinoma, Papillary / Q000150:complications / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D003264:Containment of Biohazards; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000150:complications; D033183:Interdisciplinary Communication; D007457:Iodine Radioisotopes / Q000627:therapeutic use* / Q000652:urine; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D010348:Patient Care Team; D011835:Radiation Protection; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use* / Q000652:urine; D011994:Recombinant Proteins; D006435:Renal Dialysis; D013964:Thyroid Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy; D013972:Thyrotropin
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D004921:Erythropoietin; D013972:Thyrotropin